QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.46%)
BABA   86.74 (+1.40%)
AMD   102.82 (+0.06%)
T   15.02 (+0.07%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.79%)
GE   110.55 (-1.59%)
DIS   81.05 (+1.15%)
AMC   7.99 (+2.57%)
PFE   33.17 (+3.37%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.46%)
BABA   86.74 (+1.40%)
AMD   102.82 (+0.06%)
T   15.02 (+0.07%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.79%)
GE   110.55 (-1.59%)
DIS   81.05 (+1.15%)
AMC   7.99 (+2.57%)
PFE   33.17 (+3.37%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.46%)
BABA   86.74 (+1.40%)
AMD   102.82 (+0.06%)
T   15.02 (+0.07%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.79%)
GE   110.55 (-1.59%)
DIS   81.05 (+1.15%)
AMC   7.99 (+2.57%)
PFE   33.17 (+3.37%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
QQQ   358.27 (+0.07%)
AAPL   171.21 (+0.30%)
MSFT   315.75 (+0.67%)
META   300.21 (-1.23%)
GOOGL   130.86 (-1.10%)
AMZN   127.12 (+0.90%)
TSLA   250.22 (+1.56%)
NVDA   434.99 (+0.95%)
NIO   9.04 (+1.46%)
BABA   86.74 (+1.40%)
AMD   102.82 (+0.06%)
T   15.02 (+0.07%)
F   12.42 (-1.11%)
MU   68.03 (+4.34%)
CGC   0.78 (-3.79%)
GE   110.55 (-1.59%)
DIS   81.05 (+1.15%)
AMC   7.99 (+2.57%)
PFE   33.17 (+3.37%)
PYPL   58.46 (+0.48%)
NFLX   377.60 (+0.33%)
NASDAQ:UNCY

Unicycive Therapeutics (UNCY) Price Target & Analyst Ratings

$0.86
-0.05 (-5.49%)
(As of 04:00 PM ET)
Compare
Today's Range
$0.80
$0.97
50-Day Range
$0.61
$1.23
52-Week Range
$0.40
$2.87
Volume
73,021 shs
Average Volume
2.05 million shs
Market Capitalization
$29.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.83

Unicycive Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Buy
Based on 4 Analyst Ratings

Consensus Analyst Price Target

$10.83
1,159.69% Upside
High Prediction$24.00
Average Prediction$10.83
Low Prediction$4.00
TypeCurrent
9/29/22 to 9/29/23
1 Month Ago
8/30/22 to 8/30/23
3 Months Ago
7/1/22 to 7/1/23
1 Year Ago
9/29/21 to 9/29/22
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$10.83$10.83$12.33$6.00
Predicted Upside1,159.69% Upside681.25% Upside675.68% Upside466.04% Upside
Get Unicycive Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter.


UNCY Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

UNCY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Unicycive Therapeutics Stock vs. The Competition

TypeUnicycive TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.66
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside1,090.48% Upside853.24% Upside698.13% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
8/16/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$7.00 ➝ $4.50+492.10%
7/3/2023Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$6.00 ➝ $4.00+212.50%
4/6/2023Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
K. Raja
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy
3/31/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$24.00+1,118.27%
(Data available from 9/29/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












UNCY Price Target - Frequently Asked Questions

What is Unicycive Therapeutics's consensus rating and price target?

According to the issued ratings of 4 analysts in the last year, the consensus rating for Unicycive Therapeutics stock is Buy based on the current 4 buy ratings for UNCY. The average twelve-month price prediction for Unicycive Therapeutics is $10.83 with a high price target of $24.00 and a low price target of $4.00. Learn more on UNCY's analyst rating history.

Do Wall Street analysts like Unicycive Therapeutics more than its competitors?

Analysts like Unicycive Therapeutics more than other Medical companies. The consensus rating for Unicycive Therapeutics is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how UNCY compares to other companies.

Does Unicycive Therapeutics's stock price have much upside?

According to analysts, Unicycive Therapeutics's stock has a predicted upside of 681.25% based on their 12-month price targets.

What analysts cover Unicycive Therapeutics?

Unicycive Therapeutics has been rated by HC Wainwright, and Maxim Group in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:UNCY) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -